Pharmaceuticals

Oncology Clinical Trials Market 2026–2035 expanding with increasing investment in drug development

March 23, 2026March 24, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Oncology Clinical Trials Market During 2026–2030?

The oncology clinical trials market size has experienced strong growth in recent years. This market is projected to expand from $14.99 billion in 2025 to $15.98 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.6%. The historical expansion can be attributed to factors such as limited treatment options for cancer patients, the increasing incidence of cancer globally, growing pharmaceutical and biotech R&D investments, a rising number of academic clinical research centers, and increasing awareness of clinical trial importance.

The oncology clinical trials market is poised for substantial expansion over the upcoming years. Its valuation is projected to reach $20.4 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.3%. This anticipated growth is driven by several factors, including the advancement of personalized cancer treatments, the proliferation of multicenter and international trials, the embrace of digital tools for patient monitoring, the incorporation of AI and big data into trial design, and a surge in both government and private sector investment for oncology research. Key trends anticipated during this period encompass the broadening scope of immunotherapy and targeted therapy clinical trials, a heightened emphasis on multicenter and randomized controlled studies, augmented investment in post-marketing surveillance and long-term safety assessments, the increasing uptake of cell and gene therapy trials, and the incorporation of biomarker and pharmacogenomics research into oncology studies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27371&type=smp

Which Major Factors Are Driving The Expansion Of The Oncology Clinical Trials Market?

The rising occurrence of cancer is projected to drive expansion within the oncology clinical trials market in the future. Cancer incidence is defined as the count of new cancer diagnoses observed within a particular demographic over a specified duration. This surge in cancer cases largely stems from detrimental lifestyle choices, such as inadequate nutrition, lack of physical activity, smoking, and heavy drinking, which heighten the likelihood of acquiring different forms of cancer. Oncology clinical trials play a crucial role in advancing cancer treatment by assessing novel therapies and interventions, thereby enhancing patient outcomes through evidence-based research. These trials also accelerate medical innovation by thoroughly testing safety and efficacy, thus fostering advancements in cancer prevention, diagnosis, and care. For instance, in October 2025, the National Health Service (NHS), a UK-based government health agency, reported 354,820 new cancer diagnoses in 2023, averaging 972 per day, an increase of 8,605 compared to 2022. Consequently, the growing incidence of cancer is propelling the expansion of oncology clinical trials.

How Are The Various Segments Of The Oncology Clinical Trials Market Categorized?

The oncology clinical trials market covered in this report is segmented –

1) By Phase: Phase I, Phase II, Phase III, Phase IV

2) By Study Design: Interventional, Observational, Expanded Access

3) By Therapeutic Modality: Immunotherapy, Targeted Therapy, Chemotherapy, Cell And Gene Therapy, Other Therapeutic Modalities

4) By Indication: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Blood Cancer, Other Indications

5) By Sponsor Type: Pharmaceutical And Biotech Companies, Academic And Research Institutes, Government Organizations, Other Sponsor Types

Subsegments:

1) By Phase I: Safety And Dosage Studies, Pharmacokinetics And Pharmacodynamics Studies, Biomarker Identification Studies

2) By Phase II: Efficacy And Side Effects Studies, Dose-Response Relationship Studies, Therapeutic Effectiveness Studies

3) By Phase III: Large-Scale Efficacy Studies, Comparative Effectiveness Studies, Multicenter Randomized Controlled Trials

4) By Phase IV: Post Marketing Surveillance Studies, Long-Term Safety Studies, Quality Of Life Studies

What Trends Are Affecting The Expansion Of The Oncology Clinical Trials Market?

Key companies operating in the oncology clinical trials market are prioritizing the development of technologically advanced solutions, including sophisticated bioinformatics platforms, to enhance data analysis, accelerate the recruitment of patients, and improve trial outcomes. Advanced bioinformatics platforms represent complex software systems that leverage computational tools and algorithms to gather, analyze, and interpret intricate biological and clinical data for use in research and healthcare applications. As an illustration, in Sep 2023, Deep 6 AI, a US-based healthcare technology company, introduced an AI-powered genomics module aimed at speeding up enrollment in precision medicine and oncology clinical trials. This module employs artificial intelligence and natural language processing to extract both structured and unstructured genomics data from electronic medical records, enabling the real-time identification and accurate matching of patients who possess specific genetic markers. It provides researchers with the capacity to search millions of records for more than 19,000 genes and over 30,000 mutation names, thereby considerably accelerating patient recruitment and boosting the efficiency of clinical trial design.

Which Major Firms Influence Developments In The Oncology Clinical Trials Market?

Major companies operating in the oncology clinical trials market are Pfizer Inc., Johnson & Johnson, Merck And Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Genentech Inc., BeiGene Ltd., Seagen Inc.

Read the full oncology clinical trials market report here:

https://www.thebusinessresearchcompany.com/report/oncology-clinical-trials-global-market-report

Which Region Currently Holds The Largest Share Of The Oncology Clinical Trials Market?

North America was the largest region in the oncology clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncology clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Oncology Clinical Trials Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27371&type=smp

Browse Through More Reports Similar to the Global Oncology Clinical Trials Market 2026, By The Business Research Company

Concrete Materials Market Report 2026

https://www.thebusinessresearchcompany.com/report/concrete-materials-global-market-report

Decorative Concrete Market Report 2026

https://www.thebusinessresearchcompany.com/report/decorative-concrete-global-market-report

Cellular Concrete Market Report 2026

https://www.thebusinessresearchcompany.com/report/cellular-concrete-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795